Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Baylor College of Medicine
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Texas Children's Hospital
Information provided by (Responsible Party):
Nabil Ahmed, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT01109095
First received: April 13, 2010
Last updated: August 22, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2031
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
No publications provided by Baylor College of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):